SteroTherapeutics, a Philadelphia-based, privately held biopharmaceutical company, is developing novel therapeutics for rare diseases with the strategic intent to further develop the therapeutics for larger, more common diseases. The company will combine its small company efficiencies with the development advantages afforded initially by the Orphan Drug Act; and subsequently, faster development pathways for the mainstream indications.
With our experienced management team and renowned scientific advisory board, we believe our programs have the potential to treat both large and small unmet medical diseases. Further, our partnerships with world-class leaders in academia and research will ensure our success in achieving our mission.
The company's strategic intent is to focus on platform technologies and corresponding disease pathways in diseases with significant unmet or underserved medical needs. In each individual target, SteroTherapeutics embraces the opportunity to provide safe, effective treatments, and restore an optimal quality of life.
SteroTherapeutics currently has three programs underway utilizing this strategy: ST-002, ST-003, and ST-004.
Founder & CEO
Chief Financial Officer
Head of Corporate Development
Senior VP, Regulatory Affairs
Sr VP, Scientific Affairs
Scientific Advisory Board
Professor of Medicine, Johns Hopkins University
University School of Medicine in Rome, Italy
W. Bryan Burnette
University of Vanderbilt
Arun J. Sanyal
Virginia Commonwealth University, Richmond, VA
Scott L. Friedman
Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at Icahn School of Medicine at Mount Sinai
Endocrinology, Centre hospitalier de l’Université de Montréal (CHUM), Montreal